Contents9 sections
The ACE-031 peptide is a synthetic myostatin inhibitor designed to promote muscle growth by blocking the proteins that limit muscle development. It works by mimicking the activin receptor type IIB (ActRIIB), intercepting myostatin and related ligands before they can signal muscle cells to stop growing.
ACE-031 showed significant promise in preclinical studies, with animal models demonstrating up to 40% increases in muscle volume. However, clinical trials in humans were halted after participants developed bleeding complications and vascular abnormalities. Despite this setback, the ACE-031 myostatin inhibitor research has laid the groundwork for next-generation myostatin supplements and continues to influence the development of muscle-targeted therapies.
Key Takeaways
- ACE-031 is a recombinant fusion protein that blocks myostatin, a natural protein that limits muscle growth. By inhibiting myostatin, ACE-031 allows muscles to grow larger and stronger.
- ACE-031 is a recombinant fusion protein that blocks myostatin, a natural protein that limits muscle growth. By inhibiting myostatin, ACE-031 allows muscles to grow larger and stronger.
- The ACE-031 peptide was developed to treat Duchenne Muscular Dystrophy (DMD), sarcopenia, and cachexia.
- Clinical trials were halted due to ACE-031 side effects including nosebleeds, gum bleeding, and small vascular abnormalities (telangiectasia)
- ACE-031 is available only as a research chemical. It is not FDA-approved for any therapeutic use.
What Is the ACE-031 Peptide?
ACE-031 is a recombinant fusion protein composed of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin G1 (IgG1). In simpler terms, the ACE-031 myostatin inhibitor is an engineered protein that acts as a decoy receptor, catching myostatin and related growth-inhibiting factors before they can reach muscle cells.
Quick Facts
| Property | Detail |
|---|---|
| Type | Recombinant fusion protein (soluble ActRIIB-Fc) |
| Target | Myostatin, activin A, and other TGF-beta superfamily ligands |
| Primary function | Myostatin inhibition to promote muscle growth |
| Administration | Subcutaneous injection |
| Half-life | Extended (Fc domain prolongs circulation time) |
| Clinical status | Trials halted due to safety concerns |
| Availability | Research chemical only |
How ACE-031 Was Developed
Myostatin, a member of the TGF-beta superfamily, acts as a natural brake on muscle development. It signals muscle cells to stop growing and dividing. Researchers engineered ACE-031 to intercept myostatin before it could bind to its natural receptor (ActRIIB) on muscle cells.
The Fc portion of the protein extends its half-life in the bloodstream, allowing for sustained myostatin inhibition from a single dose. This design also means ACE-031 captures not just myostatin but other related ligands like activin A, which contributed to both its therapeutic effects and its unexpected side effects.
How ACE-031 Works
When injected subcutaneously, the ACE-031 peptide circulates in the bloodstream and binds to myostatin and activin A with high affinity. This prevents these ligands from reaching their natural receptors on muscle cells, effectively removing the brake on muscle growth.
The downstream effects include:
- Muscle cell proliferation: Without myostatin signaling, muscle cells are free to divide and grow
- Muscle fiber hypertrophy: Existing muscle fibers increase in size
- Reduced muscle degradation: The myostatin pathway normally promotes muscle breakdown, which ACE-031 blocks
- Bone density improvement: ACE-031’s effects on the TGF-beta pathway also influence bone remodeling
This mechanism is fundamentally different from anabolic steroids or growth hormone, which work through hormonal pathways. ACE-031 targets a specific molecular pathway that directly governs muscle size, making it a more targeted approach to muscle growth.
ACE-031 Benefits
Muscle Growth Promotion
The primary ACE-031 benefit is its ability to promote muscle growth through myostatin inhibition. In preclinical studies using mouse models, ACE-031 produced up to a 40% increase in muscle volume in specific muscle groups. In a Phase 1 human trial with healthy postmenopausal women, a single dose of ACE-031 produced measurable increases in thigh muscle volume and total body lean mass.
Bone Density Enhancement
ACE-031 positively affects bone remodeling through its interaction with the TGF-beta pathway. Studies in postmenopausal women reported up to a 3.4% increase in lumbar spine bone mineral density. This dual effect on both muscle and bone makes ACE-031 particularly relevant for conditions where both deteriorate simultaneously, such as sarcopenia and osteoporosis.
Potential Therapy for Muscle-Wasting Conditions
ACE-031 was originally developed to treat:
- Duchenne Muscular Dystrophy (DMD): A genetic disorder causing progressive muscle degeneration due to faulty dystrophin protein
- Cachexia: Severe muscle wasting associated with cancer and chronic illness
- Sarcopenia: Age-related loss of muscle mass and strength
Early clinical data showed improvements in muscle mass and functional measures, though trials were halted before efficacy could be fully established.
Energy Metabolism Support
Research in mdx mouse models (a model for DMD) suggests that blocking myostatin with the ACE-031 peptide may improve the oxidative capacity of muscles. This enhanced energy metabolism could translate to better muscle endurance and reduced fatigue. By supporting mitochondrial function and aerobic respiration in muscle cells, ACE-031 may address not just muscle size but muscle quality and performance.
Cancer-Related Muscle Preservation
Some tumors produce myostatin, accelerating muscle loss in cancer patients. Preclinical evidence suggests ACE-031 may activate the ERK1/2 pathway and support muscle preservation in cancer-related cachexia. Beyond direct anti-wasting effects, myostatin inhibition has been associated with improved insulin sensitivity, enhanced fat metabolism, and reduced inflammation in animal models.
ACE-031 Dosage
Clinical Trial Data
| Parameter | Detail |
|---|---|
| Clinical dose range | 0.02-3 mg/kg body weight |
| Administration | Subcutaneous injection |
| Frequency | Single dose in Phase 1; planned for periodic dosing |
| Duration | Trials halted before long-term protocols established |
Important Considerations
- ACE-031 dosage protocols are based on limited clinical data from halted trials. No optimized dosing regimen has been established for any condition.
- The dose range used in human trials (0.02-3 mg/kg) produced both therapeutic effects and adverse events at higher doses.
- Self-dosing with ACE-031 carries significant uncertainty. The compound’s broad interaction with multiple TGF-beta superfamily ligands means effects extend beyond myostatin inhibition alone.
- Consult a healthcare professional before using any research peptide. Standard peptide injection technique applies for subcutaneous administration.
ACE-031 Side Effects and Why Research Was Halted
The clinical development of ACE-031 was halted primarily due to safety concerns that emerged during early human trials. While the peptide showed promising effects on muscle growth, participants experienced unexpected adverse events.
Reported Side Effects
| Side Effect | Severity | Notes |
|---|---|---|
| Nosebleeds | Mild-Moderate | Increased bleeding tendency |
| Gum bleeding | Mild-Moderate | Related to vascular effects |
| Telangiectasia | Mild | Small dilated blood vessels visible on skin surface |
| Injection site redness | Mild | Common with subcutaneous peptides |
| Hormonal changes | Moderate | Significant decrease in FSH levels in female participants |
| Potential cardiac effects | Theoretical concern | Risk of unintended muscle enlargement in the heart |
Why Trials Were Halted
The bleeding complications and vascular abnormalities indicated that ACE-031 was interfering with more than just myostatin. The compound also binds activin A and other TGF-beta superfamily members that play important roles in blood vessel integrity and tissue maintenance.
Because ACE-031’s decoy receptor design captures multiple ligands rather than selectively targeting myostatin alone, it produces off-target effects in the vascular system. The developers halted trials out of caution, concluding that the safety profile was not sufficient for continued human use without significant redesign.
This experience has driven the development of more selective myostatin inhibitors that aim to block myostatin specifically without affecting activin A or other related proteins.
ACE-031 vs. Other Myostatin Inhibitors
| Feature | ACE-031 | Follistatin | YK-11 |
|---|---|---|---|
| Type | Recombinant fusion protein | Natural glycoprotein | SARM / myostatin inhibitor |
| Mechanism | Decoy receptor (captures myostatin + activin A) | Binds and neutralizes myostatin + activin | Increases follistatin production |
| Selectivity | Low (binds multiple TGF-beta ligands) | Moderate | Moderate-High |
| Clinical status | Trials halted | Not in clinical trials for muscle | Research chemical |
| Availability | Limited research chemical | Research peptide vendors | SARM vendors |
| Safety data | Adverse events in human trials | Limited human data | Limited human data |
The ACE-031 peptide’s broad activity was both its strength (capturing multiple muscle-inhibiting factors) and its weakness (causing vascular side effects). More targeted approaches like follistatin supplementation aim to achieve similar muscle-building effects with fewer off-target complications.
The Bottom Line
The ACE-031 peptide represents an important chapter in the development of myostatin-targeted therapies.
- Its preclinical results (up to 40% increases in muscle volume and measurable bone density improvements) demonstrated the scope of ACE-031 benefits and the therapeutic potential of myostatin inhibition.
- The peptide’s ability to promote muscle growth through a non-hormonal pathway set it apart from traditional anabolic compounds.
- For anyone interested in myostatin-related muscle growth, ACE-031 is best understood as a research milestone rather than a practical option. Safer alternatives with more user experience data include follistatin and natural myostatin inhibitors like epicatechin.
Frequently Asked Questions
Disclaimer
Please read carefully
The information on this site is for educational and informational purposes only, and is not medical advice. Always consult a qualified healthcare professional before using any supplement or medication, or making changes to your health, fitness, or nutrition routine.
Not medical advice
Content here is not a substitute for professional medical advice.
Consult your doctor
Talk to your doctor before starting any supplement or new routine.
Use at your own risk
We are not responsible for adverse effects from acting on this.
Do your research
Make informed decisions about your own health.
No guarantees
Individual results vary. No claims about outcomes.
Important — Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or your local emergency number right away.
